logo
3 No-Brainer Dividend Stocks to Buy With $200 Right Now

3 No-Brainer Dividend Stocks to Buy With $200 Right Now

Yahoo7 days ago
Dividend stocks are favored by plenty of investors -- and why not? No matter where you are on your investing journey, you could use some solid dividend stocks in your portfolio.
If you're a newer investor and still have years until retirement, then owning stocks that pay a consistent dividend is a great way to turbocharge your returns. Simply reinvest your quarterly or monthly payout into your portfolio and take advantage of the magic of compounded returns.
And if you're in retirement, dividend stocks provide a reliable income stream that you can use for monthly bills, all the while reducing the amount that you're withdrawing from your account for basic living expenses. Dividend stocks can be the secret ingredient to making your retirement years happy and prosperous.
Of course, finding the best dividend stocks can sometimes be challenging. For this exercise, I used a stock screener to help me narrow the field. Because I wanted established companies, I limited the screen to companies with a market capitalization of $1 billion or more. Then I screened for companies reporting revenue growth of at least 20% and a year-to-date increase of at least 10% in price. Finally and most importantly, I limited the screen to stocks that pay a dividend yield of at least 1.75%.
Toronto-Dominion Bank (NYSE: TD), Carlyle Group (NASDAQ: CG), and Equitable Holdings (NYSE: EQH) are among the top names that I found. And best of all, you can own a share of each of them for just $200 total.
Toronto-Dominion Bank is the parent company of TD Bank, which in the U.S. operates from the Northeast to Florida. The bank is one of the biggest in Canada and the sixth-largest in North America by assets, and has nearly 28 million customers.
Earnings for the second quarter were CA$22.9 billion ($16.7 billion), up a whopping 66% on a year-to-date basis thanks to the company's sale of its 10% stake of Charles Schwab for $14.6 billion. The transaction came after TD Bank undertook a strategic review following a $3.1 billion fine it paid in 2024 in a money laundering investigation that also saw U.S. regulators impose an asset cap of $434 billion that restricts future growth in the U.S.
For shareholders, the money laundering fine was a disaster, but the company is on its way to recovery. It took CA$8 billion ($5.9 billion) from the Schwab sale for a stock buyback campaign that solidified TD Bank's stock price. The stock is up 39% so far this year, rising sharply since April, and 14 of 16 analysts who cover the stock on Yahoo! Finance have either a buy or hold recommendation.
Investors can also take comfort in knowing that Toronto-Dominion stock provides a 4.1% dividend yield and still trades 13% off its all-time high. So there's still plenty of room for growth.
Carlyle Group is a global investment firm that had $453 billion of assets under management at the end of Q1, up 6% from a year ago.
The company manages investments through private equity funds, assets, and by investing (or buying) companies that it can improve and sell for a profit or run efficiently. Carlyle has a record of investing in more than 20,000 companies since its founding, and it currently has more than 425 active investments.
Revenue in Q1 was $973.1 million, up from $688.4 million a year ago. Net income was $130 million, which was nearly double from the $65.1 million the company posted in 2024's Q1. Carlyle Group also pays a dividend yield of 2.7%. The stock is up 16% so far this year.
Equitable is a New York-based insurance and financial services company that works with individuals and small businesses. The company says it has more than 3 million clients and just over $1 billion in assets under management, up from $975 million a year ago.
It has a primary focus on retirement planning. Its insurance portfolio focuses on full life and term life policies, as well as long-term care. It also has asset management and wealth management products. Equitable stock is up 13% so far this year and provides a dividend of 1.7%.
Before you buy stock in Toronto-Dominion Bank, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Toronto-Dominion Bank wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!*
Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of July 7, 2025
Charles Schwab is an advertising partner of Motley Fool Money. Patrick Sanders has no position in any of the stocks mentioned. The Motley Fool recommends Charles Schwab and recommends the following options: short June 2025 $85 calls on Charles Schwab. The Motley Fool has a disclosure policy.
3 No-Brainer Dividend Stocks to Buy With $200 Right Now was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange
MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange

Yahoo

time17 minutes ago

  • Yahoo

MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange

MEI Pharma, Inc. (NASDAQ:MEIP) is one of the . On July 18, MEI Pharma, Inc. (NASDAQ:MEIP) announced securities purchase agreements for a private investment in public equity (PIPE) for the sale and purchase of 29,239,767 shares of common stock at a price of $3.42 per share. A modern pharmaceutical laboratory with research scientists working at their desks. The expected aggregate gross proceeds for the transaction come up to approximately $100 million before the exclusion of placement agent fees and other estimated offering expenses. MEI Pharma, Inc. (NASDAQ:MEIP) has plans to use all of the net proceeds for the launch of its treasury strategy focused on Litecoin. The transaction is thus a notable milestone for the company's long-term strategic plan, establishing MEI Pharma, Inc. (NASDAQ:MEIP) as the first and only publicly traded company to adopt Litecoin as a treasury reserve asset. Often referred to as 'silver to Bitcoin's gold,' Litecoin is a peer-to-peer cryptocurrency that Charlie Lee created in October 2011. The integration of Litecoin into its treasury operations has allowed MEI Pharma, Inc. (NASDAQ:MEIP) access to a decentralized monetary asset that complements its cash management framework. MEI Pharma, Inc. (NASDAQ:MEIP) is a pharmaceutical company that develops pharmaceutical compounds. Its programs include Voruciclib and ME-344. While we acknowledge the potential of MEIP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Earnings Preview: What to Expect From Ingersoll Rand's Report
Earnings Preview: What to Expect From Ingersoll Rand's Report

Yahoo

time17 minutes ago

  • Yahoo

Earnings Preview: What to Expect From Ingersoll Rand's Report

Ingersoll Rand Inc. (IR), valued at a market cap of $34.5 billion, is a globally diversified provider of mission-critical flow creation products and industrial solutions. Headquartered in Davidson, North Carolina, the company operates through two key segments: Industrial Technologies and Services, and Precision and Science Technologies. IR is expected to release its Q2 2025 earnings after the market closes on Thursday, July 31. Ahead of this event, analysts project the company to report an adjusted EPS of $0.76, a decline of 5% from $0.80 per share reported in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in three of the past four quarters, while missing the estimate on one occasion. More News from Barchart Warren Buffett's Berkshire Hathaway Earns $93,150 Every Hour from Coca-Cola Dividends Alone These Are the Highest Yielding Dividend Aristocrats Today (Entire List) OpenAI CEO Sam Altman Calls DeepSeek's Bluff: 'I Don't Think They Figured Out Something Way More Efficient' Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2025, analysts expect Ingersoll Rand to report an adjusted EPS of $3.22, marking an increase of 1.3% from $3.18 in fiscal 2024. In addition, its adjusted EPS is expected to grow 9.3% year-over-year to $3.52 in fiscal 2026. IR stock has crumbled 12.6% over the past 52 weeks, underperforming the S&P 500 Index's ($SPX) 13.6% gain and the Industrial Select Sector SPDR Fund's (XLI) 20.6% return during the same period. On May 1, Ingersoll Rand released its Q1 earnings, and its shares rose marginally. Its revenue rose 2.8% year-over-year to $1.7 billion, aided by recent acquisitions, but came in just below estimates. Moreover, adjusted net income declined 8.3% from the prior year to $293.2 million, also missing projections. Analysts' consensus view on IR is moderately optimistic, with a "Moderate Buy" rating overall. Among 14 analysts covering the stock, seven suggest a "Strong Buy" and seven recommend a "Hold" rating. Its mean price target of $93 represents a 8.7% premium to current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT

Yahoo

time17 minutes ago

  • Yahoo

Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT

AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted diluted EPS reaching $2.46, experiencing a 6.5% growth. The company also reported $13.343 billion in net revenue for the first quarter of 2025, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store